The GLP-1 receptor agonist liraglutide is used to treat hyperglycemia in type 2 diabetes but is also known to induce weight loss, preserve the beta cell and reduce cardiovascular risk. The mechan...
https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02237-8
Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 d...
https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02243-w
Cardiovascular disease is the major cause of morbidity and mortality, particularly in type 2 diabetes mellitus (T2DM). Novel markers of insulin resistance and progression of atherosclerosis inclu...
https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02240-z
The association between the triglyceride glucose (TyG) index and the risk of early-onset atherosclerotic cardiovascular disease (ASCVD) events or all-cause mortality in young and middle-aged peop...
https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02249-4
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been suggested to exert cardioprotective effects in patients with heart failure, possibly by improving the metabolism of ketone bodies in ...
https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02221-2